1. Home
  2. BBNX vs CVAC Comparison

BBNX vs CVAC Comparison

Compare BBNX & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBNX
  • CVAC
  • Stock Information
  • Founded
  • BBNX 2015
  • CVAC 2000
  • Country
  • BBNX United States
  • CVAC Germany
  • Employees
  • BBNX N/A
  • CVAC N/A
  • Industry
  • BBNX Medical/Dental Instruments
  • CVAC Biotechnology: Pharmaceutical Preparations
  • Sector
  • BBNX Health Care
  • CVAC Health Care
  • Exchange
  • BBNX Nasdaq
  • CVAC Nasdaq
  • Market Cap
  • BBNX 973.6M
  • CVAC 924.3M
  • IPO Year
  • BBNX 2025
  • CVAC 2020
  • Fundamental
  • Price
  • BBNX $22.87
  • CVAC $3.77
  • Analyst Decision
  • BBNX
  • CVAC Hold
  • Analyst Count
  • BBNX 0
  • CVAC 3
  • Target Price
  • BBNX N/A
  • CVAC $10.00
  • AVG Volume (30 Days)
  • BBNX 2.0M
  • CVAC 1.0M
  • Earning Date
  • BBNX 01-01-0001
  • CVAC 11-12-2024
  • Dividend Yield
  • BBNX N/A
  • CVAC N/A
  • EPS Growth
  • BBNX N/A
  • CVAC N/A
  • EPS
  • BBNX N/A
  • CVAC N/A
  • Revenue
  • BBNX $53,034,000.00
  • CVAC $70,565,734.00
  • Revenue This Year
  • BBNX N/A
  • CVAC $742.57
  • Revenue Next Year
  • BBNX N/A
  • CVAC N/A
  • P/E Ratio
  • BBNX N/A
  • CVAC N/A
  • Revenue Growth
  • BBNX 6601.12
  • CVAC 75.11
  • 52 Week Low
  • BBNX $21.81
  • CVAC $2.22
  • 52 Week High
  • BBNX $24.50
  • CVAC $5.28
  • Technical
  • Relative Strength Index (RSI)
  • BBNX N/A
  • CVAC 51.22
  • Support Level
  • BBNX N/A
  • CVAC $3.49
  • Resistance Level
  • BBNX N/A
  • CVAC $4.09
  • Average True Range (ATR)
  • BBNX 0.00
  • CVAC 0.21
  • MACD
  • BBNX 0.00
  • CVAC -0.08
  • Stochastic Oscillator
  • BBNX 0.00
  • CVAC 33.73

About CVAC CureVac N.V.

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Share on Social Networks: